Novartis Tunes Into Radiopharmaceuticals With Endocyte Buy
Executive Summary
Endocyte paid just $12m upfront a year ago for a potential first-in-class investigational radioligand therapy for prostate cancer. Novartis is buying Endocyte for a whopping $2.1bn., highlighting the company's emphasis on building in radiopharmaceuticals.
You may also be interested in...
Former Seagen CEO Siegall Takes Helm At New Biotech Morphimmune
Siegall is moving on after an unhappy exit from Seagen with a new role at another company with a novel targeted oncology platform.
Novartis Broadens VISION On Radioligands
Phase III trial presented at ASCO shows 177lutetium-PSMA-617 improved radiographic PFS and OS in advanced prostate cancer patients. Novartis execs say the firm is ready for the marketing challenge.
Lead From The Front – But Resist Micromanaging
Theragnostics’ CEO Greg Mullen aims to use his wide-ranging “hands-on” scientific and commercial experience to help clinch a $45m series A financing round that will fund a Phase I/II basket study to develop the biotech’s lead radiotherapeutic PARP inhibitor.